期刊文献+

Novel 2H-pyrazolo[4,3-c]hexahydropyridine derivatives: Synthesis, crystal structure, fluorescence properties and cytotoxicity evaluation against human breast cancer cells 被引量:1

Novel 2H-pyrazolo[4,3-c]hexahydropyridine derivatives: Synthesis, crystal structure, fluorescence properties and cytotoxicity evaluation against human breast cancer cells
原文传递
导出
摘要 A series of novel 2H-pyrazolo[4,3-c]hexahydropyridine derivatives (II) have been designed and synthesized. The target compounds have been identified by elemental analysis and spectral ( 1 H NMR, IR, and MS) data and the absolute configuration of compound (II 1 ) was confirmed by single crystal X-ray diffraction. The cytotoxicity of the target compounds have been evalu- ated in vitro against two human breast cancer cell lines MCF-7 and MDA-MB-231 by MTT assay. Most compounds exhibited good inhibition, and compounds II 21 (IC 50=4.7μM for MCF-7 and IC 50=9.3μM for MDA-MB-231), II 33 (IC 50=2.4μM for MCF-7 and IC 50=4.2μM for MDA-MB-231) and II 40 (IC 50=3.3μM for MCF-7 and IC 50 =8.6μM for MDA-MB-231) displayed better inhibitory activity than 5-fluorouracil (IC 50=4.8μM for MCF-7 and IC 50=9.6μM for MDA-MB-231, respectively). Flow cytometric analysis and DNA fragmentation suggest that II 33 is cytotoxic and able to induce the apoptosis of MCF-7 cells. The fluorescence properties of compounds II 1 , II 6 , II 11 , II 16 , II 23 , II 28, and II 35 were also studied and compound II 28 afforded the highest photoluminescence quantum yield (38%). A series of novel 2H-pyrazolo[4,3-c]hexahydropyridine derivatives (II) have been designed and synthesized. The target com- pounds have been identified by elemental analysis and spectral (1H NMR, IR, and MS) data and the absolute configuration of compound (IIl) was confirmed by single crystal X-ray diffraction. The cytotoxicity of the target compounds have been evalu- ated in vitro against two human breast cancer cell lines MCF-7 and MDA-MB-231 by MTT assay. Most compounds exhibited good inhibition, and compounds II21 (IC50 = 4.7 μM for MCF-7 and IC50 = 9.3 μM for MDA-MB-231), 1133 (IC50 = 2.4 μM for MCF-7 and IC50 = 4.2 gM for MDA-MB-231) and 114o (IC50 = 3.3 μM for MCF-7 and IC5o =8.6 μM for MDA-MB-231) dis- played better inhibitory activity than 5-fluorouracil (IC50 = 4.8 μM for MCF-7 and IC50 = 9.6 I, tM for MDA-MB-231, respec- tively). Flow cytometric analysis and DNA fragmentation suggest that II33 is cytotoxic and able to induce the apoptosis of MCF-7 cells. The fluorescence properties of compounds IIl, II6, II11,II16, II23, Il2s, and II3s were also studied and compound Ilzs afforded the highest photoluminescence quantum yield (38%).
出处 《Science China Chemistry》 SCIE EI CAS 2013年第6期702-715,共14页 中国科学(化学英文版)
基金 supported by Zooblast-molecular Biology Laboratory of Shanghai Normal University supported by the National Natural Science Foundation of China (21042010, 21102092 and30870560) the Key Scientific "Twelfth Five-Year" National Technology Support Program (2011BAE06B01-17) the Innovation Project of Shanghai Education Commission (12YZ078) the Key Project of the Science and Technology Commission of Shanghai 105405503400) the Leading Academic Discipline Project of Shanghai Normal University (DZL808) Shanghai Key Laboratory of Rare Earth Functional Materials, Shanghai Normal University (07dz22303)
关键词 化学 C-C 原理 方法 实验 pyrazolopyridine, synthesis, crystal structure, breast cancer cells, cytotoxicity evaluation, apoptosis, fluorescence prop-erties
  • 相关文献

参考文献1

二级参考文献16

  • 1Simona, F.; Riccardo, A.; Marilisa, B.; Margherita, G.; Chiara, C.; Isabelle, Z. C.; Michel, B.; Elise, C. K.; Giacomo, D. L. J. Proteome Res. 2007, 6, 4330.
  • 2Jamieson, C. H.; Ailles, L. E.; Dylla, S. J.; Muijtjens, M.; Jones, C.; Zehnder, J. L.; Gotlib, J.; Li, K.; Manz, M. G.; Keating, A.; Sawyers, C. L.; Weissman, I. L. New Engl. J. Med. 2004, 351,657.
  • 3Michor, F. Cell 2007, 25, 1114.
  • 4Dimmock, J. R.; Das, U.; Gul, H. I.; Alcom, J.; Shrivastav, A.; George, T.; Nienaber, K. H.; Kawase, M.; Kan, N.; Tanaka, T.; Tani, S.; Werbovetz, K. A.; Yakovicb, A. J.; Manavathu, E. K.; Stables, J. P. Eur. J. Med. Chem. 2006, 41,577.
  • 5Dimmock, J. R.; Das, U.; Kawase, M.; Sakagami, H.; Ideo, A.; Shimada, J.; Moln~, J.; Bargth, Z.; Bata, Z. Bioorg. Med. Chem. 2007, 15, 3373.
  • 6Dimmock, J. R.; Das, U.; Gul, H. I.; Alcorn, J.; Shrivastav, A.; Sharrna, R. K.; De Clercq, E.; Balzarini, J. Eur. J. Med. Chem. 2007, 42, 71.
  • 7Dimmock, J. R.; Jha, A.; Mukherjee, C.; Prasad, A. K.; Parmar, V. S.; De Clercq, E.; Balzarini, J.; Stables, J. P.; Manavathu, E. K.; Shrivastav, A.; Sharma, R. K.; Nienaber,K. N.; Zello, G. A. Bioorg. Med. Chem. 2007, 15, 5854.
  • 8Pati, H. N.; Das, U.; Quail, J. W.; Kawase, M.; Sakagami, H.; Dimmock, J. R, Eur. J. Med. Chem. 2008, 43, 1.
  • 9Odinets, I. L.; Artyushin, O. I.; Evgenii, I.; Goryunov, E. I. Lyssenko, K. I.; Rybalkina, E. Y.; Kosilkin, I. V. Timofeeva, T. V.; Antipin, M. Y. J. Heterocyclic Chem 2005, 16, 497.
  • 10Tripathi, R. P.; Singh, N.; Pandey, J.; Yadav, A.; Chaturvedi, V.; Bhatnagar, S.; Gaikwad, A. N.; Sinha, S. K.; Kumar, A.; Shukla, P. K. Eur. J. Med. Chem. 2009, 44, 1705.

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部